期刊文献+

112株新生儿败血症致病菌的分布及耐药性分析 被引量:5

Distribution and Resistance Analysis of 112 Strains of Pathogenic Bacteria of Neonatal Septicemia
下载PDF
导出
摘要 目的:分析新生儿败血症的病原学分布及其耐药变迁情况,为临床及时明确病原、正确选用抗菌药物提供参考。方法:对苏州市立医院2009年6月—2012年6月间确诊的111例新生儿败血症病例的资料、血培养结果和药敏试验情况进行回顾性分析。结果:111例患者中检出病原菌112株,其中革兰阳性菌为78株(69.64%),革兰阴性菌为34株(30.36%);革兰阳性菌以凝固酶阴性葡萄球菌(CNS)为主,革兰阴性菌以肺炎克雷伯菌、大肠埃希菌为常见;革兰阳性球菌对青霉素、红霉素、苯唑西林的耐药性较高,对万古霉素、利奈唑胺未发现产生耐药;革兰阴性杆菌对氨苄西林产生耐药,对亚胺培南、阿米卡星、哌拉西林-他唑巴坦具有较高的敏感性。结论:CNS是导致新生儿败血症的主要病原菌,耐甲氧西林凝固酶阴性葡萄球菌(MRCNS)和产超广谱β-内酰胺酶(ESBLs)肺炎的克雷伯菌、大肠埃希菌的比例呈上升趋势,临床应重视新生儿败血症的病原菌耐药性检测,根据血培养药敏结果合理选用抗菌药物。 Objective: To analyse the distribution of pathogens and the change of drug resistance in neonatal septicemia and to help us to correctly use antibiotics. Methods: The results of clinical data,blood culture and drug susceptibility test in 111 cases of neonatal septicemia were retrospectively analyzed. Results: A hundred and twelve stains were detected from 111 cases, with a result of Gram-positive accounting for 78 stains (69.64%) and Gram-negative accounting for 34 stains (30.36%). The main strains were CNS of Gram-positive and K.pneumoniae, E.coli of Gram-negative; Gram-positive cocci demonstrated a strong resistance to penicillin, erythromycin, oxacillin and vancomycin(linezolid finds no resistance); Gram-negative bacilli resistant to ampicillin and to imipenem, amikacin and piperacillin-tazobactam with high sensitivity. Condusion: CNS has become the main pathogenic bacteria of neonatal septicemia, MRCNS and K.pneumoniae, E. coli with ESBLs were increased. Much more attention should be paid to drug resistance detection and choice of sensitive antibiotics based on the drug sensitivity tests.
出处 《抗感染药学》 2013年第1期59-62,共4页 Anti-infection Pharmacy
关键词 新生儿 败血症 病原菌 耐药性 newborn septicemia pathogenic bacteria drug resistance
  • 相关文献

参考文献3

二级参考文献10

共引文献1043

同被引文献51

  • 1邵肖梅,叶鸿瑶,丘小汕.实用新生儿学[M].4版.北京:人民卫生出版社,2011:807-808.
  • 2中华人民共和国卫生部药政司.抗菌药物临床研究指导原则[S].,1993.2-8.
  • 3国家药品不良反应监测中心.药品不良反应报告和监测工作手册[EB/OL].http//www.cdr.gov.cn/zscx/qtdz-zl/index.shtml.2010-01-24.
  • 4Kocher S,Muller W,Resch B. Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants:a systematic review[J].International Journal of Antimicrobial Agents,2010,(02):106-110.doi:10.1016/j.ijantimicag.2010.03.030.
  • 5Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment[J].J Antimicrob Chenmother,2011,(14):iv7-iv15.
  • 6Pharmacia & Upjohn Company. Zyvox:linezolid injection, linezolid tablets, linezolid for oral suspension package insert[M].Kalamazoo,MI:Pharmacia & Upjohn Company,2002.
  • 7Jungbluth GL,Welshman IR,Hopkins NK. Impact of gestational and postnatal age on linezolid disposition in neonates and young infants[J].Pediatric Research,2002.464A.
  • 8Chiappini E,Conti C,Galli L. Clinical efficacy and tolerability of linezolid in pediatric patients:a systematic review[J].Clinical Therapeutics,2010.66-68.
  • 9Garazzino S,Tovo PA. Clinical experience with linezolid in infants and children[J].Journal of Antimicrobial Chemotherapy,2011,(04):iv23-iv41.
  • 10Kaplan SL,Deville JG,Yogev R. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children[J].Pediatric Infectious Disease Journal,2003.677-685.

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部